Senator Bernie Sanders pointed to UnitedHealth's $5.48 billion in second-quarter 2026 profit as evidence the company's requested 25% average rate increase for its DC small-group HMO and PPO plans could not be justified (Bernie Sanders, X, July 21, 2026; UnitedHealth Group, July 16, 2026). The claim conflates two figures a rate actuary keeps separate: trailing consolidated GAAP earnings spanning every state and product line, and a single, prospective state filing that must independently clear its own morbidity and trend assumptions before a regulator signs off.

Sanders made the connection explicit in a July 21, 2026 post on X, days after both numbers became public: "Corporate greed is UnitedHealth making a $5.48 billion profit last quarter (up 60% from last year), spending $33 billion in stock buybacks since 2022, paying its CEO over $60 million last year while it works to hike premiums by up to 25% next year" (Bernie Sanders, X, July 21, 2026). The arithmetic in that post checks out against the earnings release: $5.48 billion in net earnings this quarter against $3.41 billion a year earlier is a 60.7% increase (UnitedHealth Group, July 16, 2026). What the post elides is that the 25% figure belongs to one insurer's HMO and PPO products in one jurisdiction's small-group market, not a company-wide rate action, and that the mechanism connecting consolidated profit to that specific filing runs through several actuarial checkpoints Sanders' post skips entirely.

The $5.48 Billion Figure Is Three Businesses Blended Into One Number

UnitedHealth Group's Q2 2026 net earnings of $5.48 billion sit on top of $112.0 billion in consolidated revenue and $8.0 billion in operating earnings, up 55% year over year (UnitedHealth Group, July 16, 2026). That consolidated figure aggregates two segments with fundamentally different economics. UnitedHealthcare, the insurance arm that actually underwrites the DC small-group business, produced $86.0 billion of revenue and $3.9 billion of operating earnings, a 4.6% operating margin, while serving 48.5 million people across commercial, Medicare, and Medicaid lines whose total membership fell 525,000 sequentially (UnitedHealth Group, July 16, 2026). Optum, the services and pharmacy-benefit arm that never touches DC's rate filing at all, produced $65.7 billion of revenue and $4.0 billion of operating earnings on a 6.2% margin (UnitedHealth Group, July 16, 2026). Roughly half the parent company's operating profit did not come from selling insurance.

Inside UnitedHealthcare itself, the medical care ratio, the insurance-specific analogue to a loss ratio, improved to 86.7% in Q2 2026 from 89.4% a year earlier (UnitedHealth Group, July 16, 2026). A falling medical care ratio is better performance for the carrier, not worse, and roughly 40% of that 270-basis-point improvement traced to $860 million of net favorable prior-period development, mostly tied to 2026 dates of service, rather than to pricing alone. That reserve dynamic is national and blended across every state and product UnitedHealthcare writes; it says nothing about whether DC's specific small-group HMO book, priced against DC-specific provider contracts, DC-specific morbidity, and DC-specific risk adjustment transfers, is running rich or thin. A national medical care ratio improving is consistent with individual state filings still needing double-digit increases, because national blended experience and a single state-and-product rate cell are different populations measured over different time horizons.

What a DC Rate Filing Has to Show That a Profit Number Does Not

DC's Department of Insurance, Securities and Banking published preliminary 2027 rates for 181 plans across CareFirst BlueCross BlueShield, Kaiser Permanente, and UnitedHealthcare on June 8, 2026 (DC DISB, June 8, 2026). UnitedHealthcare proposed roughly 25% average increases across its two small-group HMO products and its PPO plan. That sits well above the market: CareFirst proposed 9.8% (HMO) and 4.5% (PPO) for small group, and Kaiser proposed 8%, putting the DC-wide small-group average around 10.4%, with the individual market averaging roughly 9.5% (DC DISB, June 8, 2026). UnitedHealthcare's ask is more than double the jurisdiction's blended small-group average, which is the actual comparison a rate actuary would draw, not the comparison to the parent company's consolidated profit.

An actuarial memorandum supporting a DC filing has to justify the requested rate against a specific set of prospective inputs: projected medical and pharmacy trend for the coming plan year, expected morbidity of the specific risk pool being rated, provider unit-cost changes embedded in DC-area contracts, projected risk adjustment transfers under the ACA's 3Rs framework, administrative expense and premium tax load, and a contribution-to-surplus or profit margin assumption that state regulators separately evaluate for reasonableness. None of those inputs references UnitedHealth Group's consolidated net income, its buyback program, or its CEO's pay package. A regulator reviewing the filing is testing whether the DC small-group book's own projected claims and expenses justify a 25% increase, not whether the parent company can afford to charge less. That is also why a high consolidated profit does not automatically mean a specific filing is padded: if DC small-group morbidity, provider reimbursement, or risk-pool composition genuinely deteriorated more than the trend baked into 2026 rates, a 25% correction can be actuarially supportable even in a quarter where the parent reports record earnings elsewhere.

FigureWhat it measuresRelevant to the DC rate filing?
$5.48B Q2 2026 net earningsConsolidated GAAP profit, all segments, all statesNo, not a rate-filing input
86.7% medical care ratioUnitedHealthcare's national blended claims-to-premium ratioDirectional context only, not DC-specific
25% proposed DC small-group increaseUnitedHealthcare's own HMO/PPO filing for one marketYes, the actual filing under review
10.4% DC small-group market averageBlended average across CareFirst, Kaiser, UnitedHealthcareYes, the relevant peer benchmark
$33B buybacks since 2022 (per Sanders)Parent-level capital allocationNo, but shapes public/political scrutiny

The Medical Loss Ratio Backstop Operates on a Lag, Not in Real Time

The mechanism that is actually supposed to catch overpriced rates sits inside the ACA's medical loss ratio rule, not inside the rate-review process itself. Insurers in the individual and small-group markets must spend at least 80% of premium on claims and quality-improvement activities, measured as a three-year rolling average by state and market segment; insurers that fall short must rebate the shortfall to policyholders, while the large-group threshold is 85% (NAIC, Medical Loss Ratio overview; CMS, Medical Loss Ratio Fact Sheet). That is a retrospective test applied after the fact to realized experience in a specific state-and-market cell, not a prospective ceiling a regulator applies when approving next year's rate. If UnitedHealthcare's DC small-group HMO book collects a 25% increase in 2027 and actual claims come in materially better than the pricing assumed, the MLR calculation catches the excess and forces a rebate on a rolling three-year lag, not an immediate clawback. That lag is precisely why a single strong earnings quarter cannot be read as proof that a specific state filing is excessive: the corrective mechanism for pricing that turns out too rich already exists, it just operates on a multi-year cycle rather than a quarterly one, and it applies at the state-and-product level where the risk was actually written, not at the parent company level where Sanders' post pointed.

Buybacks and Executive Pay Sit Outside the Rate Filing, Not Outside the Politics

UnitedHealth's 2026 proxy statement confirms Stephen Hemsley, who took over as CEO in May 2025, draws a $1 million annual base salary with no annual cash incentive, alongside a one-time $60 million equity award in nonqualified stock options that cliff-vests over three years, with no additional equity grants planned during that period (UnitedHealth Group, 2026 Proxy Statement). Public buyback trackers put UnitedHealth's repurchases at roughly $7 billion in 2022, $8 billion in 2023, and $9 billion in 2024, with the company guiding to at least $5 billion more in 2026, a trajectory broadly consistent with the cumulative $33 billion since 2022 that Sanders cited, though the company's own 10-K discloses the year-by-year totals more precisely than any single secondary aggregation (UnitedHealth Group SEC filings; public buyback data compiled by FinanceCharts and MacroTrends).

Neither figure is an allowed expense or rating input in an actuarial memorandum: a state regulator reviewing UnitedHealthcare's DC filing does not net Hemsley's equity award or the parent's buyback program against the requested rate. But treating that as the end of the analysis misses the other half of the reconciliation. Capital allocation decisions made at the holding-company level are funded from the same consolidated free cash flow that includes UnitedHealthcare's insurance margins, and state hearing officers, legislators, and consumer advocates routinely reference parent-level financial results in public rate hearings even when those figures carry no formal actuarial weight. DC's own rate review includes a public hearing in September 2026 before final rates are set, and testimony citing UnitedHealth Group's consolidated earnings, buybacks, or executive pay is a normal, if actuarially imprecise, feature of that hearing (DC DISB, June 8, 2026). Buybacks and compensation shape the political and regulatory environment a filing gets reviewed in, including how skeptically a commissioner reads a requested profit margin, even though they never enter the rate calculation itself.

The Filing Sits Inside a Broader 2027 Rate Cycle, Not Ahead of It

UnitedHealthcare's 25% DC ask is unusual relative to its own local peers but not unusual relative to the national 2027 filing season. Preliminary rate filings across 77 ACA Marketplace insurers in 16 states and DC show a median proposed increase of 14% for 2027, with 20 of those insurers requesting more than 20% (KFF, July 2026). KFF attributes the increases to underlying medical and prescription-drug cost trend running near 10% for 2027, above the roughly 8% average of recent years, compounded by a sicker risk pool that added about four percentage points to 2026 premiums and is expected to add roughly four more in 2027 as subsidy changes reshape marketplace enrollment (KFF, July 2026; Peterson-KFF Health System Tracker, July 2026). If those increases hold, cumulative marketplace premiums would rise by more than a third between 2025 and 2027. UnitedHealthcare's DC small-group filing is a distinct market segment from the individual ACA marketplace KFF's analysis covers, but the same cost drivers, elevated provider trend and adverse risk-pool shifts, are the plausible actuarial explanation for why one carrier's small-group book would need a correction well above its local competitors, independent of anything happening on the parent company's income statement.

Reconciling the Two Numbers

The actuarially defensible version of Sanders' critique is not that $5.48 billion in profit proves the DC filing is padded; a rate actuary cannot draw that line directly. It is that a company reporting record consolidated earnings and returning tens of billions to shareholders since 2022 invites more public and regulatory scrutiny of how conservatively it sets its profit margin assumption in each individual filing, and DC's commissioner has full authority to challenge that margin assumption specifically, alongside the trend and morbidity assumptions, at the September hearing. The rate review, the MLR rebate mechanism, and the political scrutiny are three separate checks operating on three separate timelines and three separate units of analysis: a prospective state-and-product filing, a retrospective three-year rolling rebate test, and an ongoing public-legitimacy conversation about capital allocation. Conflating any two of them, treating consolidated profit as proof a filing is excessive, or treating an approved rate as proof a company's broader capital allocation is above criticism, mistakes which checkpoint is actually doing the work.

Further Reading

Sources